CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
Oxybutynin 3% geldrug
Likely dose
Oxybutynin 3% gel (specific dosing/frequency not detailed)AI-extracted
Key inclusion· 4
  • ✓Age 12-25 years
  • ✓Meet consensus criteria for primary focal hyperhidrosis: focal, visible, excessive sweating ≥6 months duration with ≥2 of: bilateral/symmetric, impairs daily activities, ≥1 episode/week, onset <25 years, positive family history, or cessation during sleep
  • ✓Moderate to severe hyperhidrosis (HDSS score 3 or 4)
  • ✓Hyperhidrosis affecting bilateral axillae (may include concurrent involvement of palms, soles, face, or other areas)
Key exclusion· 10
  • ✕Hyperhidrosis duration <6 months or secondary to underlying infectious, endocrine, or neurologic disorder
  • ✕Botulinum toxin injections to axillae or affected areas within 12 weeks
  • ✕Oral anticholinergic medications or topical aluminum chloride within 4 weeks
  • ✕Active skin inflammation or infection affecting the axilla

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02633371
NCT02633371N/ACompleted
CompareCT.gov

A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults

University of Colorado, Denver·interventional·Posted Dec 17, 2015·Updated Jun 19, 2018

In Brief

A clinical study evaluating Oxybutynin 3% gel for Hyperhidrosis. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This is a single-center, prospective, open-label, outpatient pilot study evaluating the efficacy and tolerability of oxybutynin gel for axillary hyperhidrosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperhidrosis
CountriesUnited States
CollaboratorsSociety for Pediatric Dermatology

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 17, 2015
Enrollment StartFeb 1, 2016
Primary CompletionJun 1, 2016
Study CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.5 years ago

Interventions

Oxybutynin 3% geldrug